Recursion Pharmaceuticals Inc (RXRX)

NASDAQ
11.66
+0.77(+7.07%)
After Hours
11.66
0.00(0.00%)
- Real-time Data
  • Volume:
    1,149,863
  • Day's Range:
    10.92 - 11.70
  • 52 wk Range:
    4.92 - 23.86

RXRX Overview

Prev. Close
10.89
Day's Range
10.92-11.7
Revenue
18.06M
Open
10.96
52 wk Range
4.92-23.86
EPS
-1.37
Volume
1,149,863
Market Cap
2.02B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,124,057
P/E Ratio
-8.77
Beta
1.47
1-Year Change
-55.86%
Shares Outstanding
173,076,691
Next Earnings Date
Nov 09, 2022
What is your sentiment on Recursion Pharmaceuticals?
or
Market is currently closed. Voting is open during market hours.

Recursion Pharmaceuticals Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Recursion Pharmaceuticals Inc Company Profile

Recursion Pharmaceuticals Inc Company Profile

Employees
330

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Read More

Analyst Price Target

Average16.00 (+37.22% Upside)
High38
Low7
Price11.66
No. of Analysts4
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyStrong BuyNeutral
Technical IndicatorsStrong BuyStrong BuyStrong BuyNeutralStrong Sell
SummaryStrong BuyStrong BuyStrong BuyBuySell
  • SCAM
    0